Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
34
MAZE Quote, Financials, Valuation and Earnings
Last price:
$40.34
Seasonality move
:
--
Day range:
$38.95 - $40.75
52-week range:
$6.71 - $43.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
501.13x
P/B ratio:
5.11x
Volume:
210.5K
Avg. volume:
417.6K
1-year change:
--
Market cap:
$1.9B
Revenue:
$167.5M
EPS (TTM):
-$2.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MAZE
Maze Therapeutics, Inc.
|
$428.6K | -$0.78 | -100% | -4.46% | $47.33 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$3.5M | -$0.90 | -7.14% | -69.46% | $52.67 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.62 | -- | -23.21% | $52.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MAZE
Maze Therapeutics, Inc.
|
$40.32 | $47.33 | $1.9B | -- | $0.00 | 0% | 501.13x |
|
CDT
CDT Equity, Inc.
|
$1.51 | -- | $2.5M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$14.87 | $52.67 | $465.3M | -- | $1.03 | 0% | 23.72x |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
$27.86 | $52.17 | $1.3B | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MAZE
Maze Therapeutics, Inc.
|
5.99% | 0.000 | 1.94% | 17.36x |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.944 | 27% | 1.13x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.162 | 0.07% | 12.39x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.530 | 0.2% | 16.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MAZE
Maze Therapeutics, Inc.
|
-$571K | -$33M | -30.65% | -35.16% | -- | -$24.7M |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
Maze Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns MAZE or CDT?
CDT Equity, Inc. has a net margin of -- compared to Maze Therapeutics, Inc.'s net margin of --. Maze Therapeutics, Inc.'s return on equity of -35.16% beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About MAZE or CDT?
Maze Therapeutics, Inc. has a consensus price target of $47.33, signalling upside risk potential of 17.39%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Maze Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe Maze Therapeutics, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics, Inc.9 0 0 CDTCDT Equity, Inc.0 0 0 -
Is MAZE or CDT More Risky?
Maze Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MAZE or CDT?
Maze Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics, Inc. pays -- of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or CDT?
Maze Therapeutics, Inc. quarterly revenues are --, which are smaller than CDT Equity, Inc. quarterly revenues of --. Maze Therapeutics, Inc.'s net income of -$30.1M is lower than CDT Equity, Inc.'s net income of -$7.1M. Notably, Maze Therapeutics, Inc.'s price-to-earnings ratio is -- while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics, Inc. is 501.13x versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns MAZE or LENZ?
LENZ Therapeutics, Inc. has a net margin of -- compared to Maze Therapeutics, Inc.'s net margin of -133.6%. Maze Therapeutics, Inc.'s return on equity of -35.16% beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About MAZE or LENZ?
Maze Therapeutics, Inc. has a consensus price target of $47.33, signalling upside risk potential of 17.39%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $52.67 which suggests that it could grow by 254.18%. Given that LENZ Therapeutics, Inc. has higher upside potential than Maze Therapeutics, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than Maze Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics, Inc.9 0 0 LENZLENZ Therapeutics, Inc.5 0 0 -
Is MAZE or LENZ More Risky?
Maze Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MAZE or LENZ?
Maze Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Maze Therapeutics, Inc. pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or LENZ?
Maze Therapeutics, Inc. quarterly revenues are --, which are smaller than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. Maze Therapeutics, Inc.'s net income of -$30.1M is lower than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, Maze Therapeutics, Inc.'s price-to-earnings ratio is -- while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics, Inc. is 501.13x versus 23.72x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M LENZLENZ Therapeutics, Inc.23.72x -- $12.5M -$16.7M
-
Which has Higher Returns MAZE or LIMN?
Liminatus Pharma has a net margin of -- compared to Maze Therapeutics, Inc.'s net margin of --. Maze Therapeutics, Inc.'s return on equity of -35.16% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About MAZE or LIMN?
Maze Therapeutics, Inc. has a consensus price target of $47.33, signalling upside risk potential of 17.39%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Maze Therapeutics, Inc. has higher upside potential than Liminatus Pharma, analysts believe Maze Therapeutics, Inc. is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics, Inc.9 0 0 LIMNLiminatus Pharma0 0 0 -
Is MAZE or LIMN More Risky?
Maze Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MAZE or LIMN?
Maze Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics, Inc. pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or LIMN?
Maze Therapeutics, Inc. quarterly revenues are --, which are larger than Liminatus Pharma quarterly revenues of --. Maze Therapeutics, Inc.'s net income of -$30.1M is higher than Liminatus Pharma's net income of --. Notably, Maze Therapeutics, Inc.'s price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics, Inc. is 501.13x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns MAZE or ORKA?
Oruka Therapeutics, Inc. has a net margin of -- compared to Maze Therapeutics, Inc.'s net margin of --. Maze Therapeutics, Inc.'s return on equity of -35.16% beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M -
What do Analysts Say About MAZE or ORKA?
Maze Therapeutics, Inc. has a consensus price target of $47.33, signalling upside risk potential of 17.39%. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $52.17 which suggests that it could grow by 87.25%. Given that Oruka Therapeutics, Inc. has higher upside potential than Maze Therapeutics, Inc., analysts believe Oruka Therapeutics, Inc. is more attractive than Maze Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics, Inc.9 0 0 ORKAOruka Therapeutics, Inc.11 0 0 -
Is MAZE or ORKA More Risky?
Maze Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.394, suggesting its less volatile than the S&P 500 by 139.44%.
-
Which is a Better Dividend Stock MAZE or ORKA?
Maze Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Maze Therapeutics, Inc. pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or ORKA?
Maze Therapeutics, Inc. quarterly revenues are --, which are smaller than Oruka Therapeutics, Inc. quarterly revenues of --. Maze Therapeutics, Inc.'s net income of -$30.1M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, Maze Therapeutics, Inc.'s price-to-earnings ratio is -- while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics, Inc. is 501.13x versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
